- Home
- SYPR vs BTAI Comparison
SYPR vs BTAI Comparison
Compare SYPR & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SYPR | BTAI |
|---|---|---|
| Founded | 1997 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.7M | 49.2M |
| IPO Year | 1994 | 2018 |
Fundamental Metrics
Financial Performance| Metric | SYPR | BTAI |
|---|---|---|
| Price | $2.42 | $1.58 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.80 |
| AVG Volume (30 Days) | 70.2K | ★ 463.9K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $123,055,000.00 | $752,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $441.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.42 | $1.17 |
| 52 Week High | $3.72 | $9.26 |
Technical Indicators
Market Signals| Indicator | SYPR | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 59.68 | 36.65 |
| Support Level | $2.11 | $1.50 |
| Resistance Level | $2.72 | $1.89 |
| Average True Range (ATR) | 0.21 | 0.11 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 56.45 | 13.77 |
Price Performance
Historical ComparisonAbout SYPR Sypris Solutions Inc.
Sypris Solutions Inc is a USA-based company engaged in providing truck components, oil and gas pipeline components, and aerospace and defense electronics. The company offers a range of manufacturing, engineering, design, and other technical services. The business activity of the firm is functioned through Sypris Technologies and Sypris Electronics segments. Sypris Technologies segment is engaged in the sales of machined, welded, and heat-treated steel components for heavy commercial vehicle and high-pressure energy pipeline applications whereas the Sypris Electronics segment is engaged in the sale of manufacturing services, technical services, and products to customers in the market for aerospace and defense electronics. Sypris derives the revenue from the Technologies segment.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.